Seeking Alpha

Boston Scientific (BSX +5%) gains on a healthy beat to its Q4 bottom line this morning, despite...

Boston Scientific (BSX +5%) gains on a healthy beat to its Q4 bottom line this morning, despite net earnings falling 44% Y/Y as the medical-device maker was hit by higher restructuring-related charges. Revenue was down slightly as declines in cardiology products offset growth in other areas. The company gave upbeat guidance for FY13, now expecting to earn between $7.05B to $7.35B, compared with the $7.12B expected by the Street, and announced a $1B share buyback.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs